CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Study sponsor: Candel Therapeutics, Inc. · CADL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-12-31Actual
Enrollment · participants90Actual
Source updated2026-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.